Lobular inflammation: polymorphonuclear cells in association with ballooned hepatocytes; pericellular fibrosis; mild chronic inflammation may be seen. Portal inflammation: mild to moderate.

Anyone, of any ethnicity, can get cystic fibrosis. But for decades it has been overlooked in people of color, leading to misdiagnoses and dismal health disparities. Terry Wright takes a pulmonary ...

Cystic fibrosis is a genetic disorder that affects roughly 40,000 Americans. The condition is caused by a mutation in the patient's cystic fibrosis transmembrane conductance regulator (CFTR) gene, ...

The desire to have children represents one of the most fundamental human experiences, yet for people living with cystic fibrosis, the path to parenthood can feel uncertain and complex. You might ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype ...

Among the roughly 15,000 cystic fibrosis patients, acute myocardial infarction (MI) and atrial fibrillation (Afib) were the other most commonly identified cardiac disorders, each present in about ...

Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmonary fibrosis is needed. In a phase 3 ...

The trial enrolled 1176 patients across 44 countries with fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), such as autoimmune ILDs, hypersensitivity pneumonitis, and unclassifiable ...

Co-founded by Landmark BioVentures and researchers from Aix-Marseille University, Massalia will develop its sole-in-class therapeutic platform targeting conditions interlinking challenging diseases: ...